Telix Pharmaceuticals Chair Resigns as Board Installs Interim Successor

An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.

Telix Pharmaceuticals has announced the resignation of Board Chair and Non-Executive Director Tiffany Olson, effective 3 February 2026, and the appointment of long-standing independent Non-Executive Director Dr. Mark Nelson as Interim Chair. The board said it is in the advanced stages of appointing additional Non-Executive Directors and a new independent Chair, while stressing that the leadership change will not affect the company’s near-term milestones or long-term growth strategy, and characterising 2026 as a pivotal year for its expanding commercial business and pipeline.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$20.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals is a Melbourne-headquartered biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and related medical technologies. Listed on both the ASX and Nasdaq, the company operates across the United States, Europe, Japan, Brazil, Canada and the UK, with a portfolio of clinical and commercial-stage products targeting significant unmet medical needs in oncology and rare diseases.

YTD Price Performance: -5.80%

Average Trading Volume: 2,058,685

Technical Sentiment Signal: Sell

Current Market Cap: A$3.57B

For an in-depth examination of TLX stock, go to TipRanks’ Overview page.